α-Helical CRF (9-41) trifluoroacetate salt structure
|
Common Name | α-Helical CRF (9-41) trifluoroacetate salt | ||
---|---|---|---|---|
CAS Number | 99658-03-4 | Molecular Weight | 3826.36 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | 717.1±60.0 °C at 760 mmHg | |
Molecular Formula | C166H274N46O53S2 | Melting Point | N/A | |
MSDS | USA | Flash Point | 387.5±32.9 °C |
Use of α-Helical CRF (9-41) trifluoroacetate saltα-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2]. |
Name | Corticotropin Releasing Factor Antagonist |
---|---|
Synonym | More Synonyms |
Description | α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo[1][2]. |
---|---|
Related Catalog | |
In Vivo | α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values[1]. α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity[2]. Animal Model: Adult Sprague-Dawley rats[1] Dosage: 10 μg Administration: The third or lateral ventricle of the brain injection; 10 μg once Result: Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress. Animal Model: Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)[1] Dosage: 10 μg Administration: Lateral ventricle brain injection; 10 μg once Result: Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF). Animal Model: Male Wistar rats with rhlL-1/β injection[2] Dosage: 100 ng/kg Administration: Intracerebroventricularly injection; 100 ng/kg once Result: Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 717.1±60.0 °C at 760 mmHg |
Molecular Formula | C166H274N46O53S2 |
Molecular Weight | 3826.36 |
Flash Point | 387.5±32.9 °C |
Exact Mass | 540.075745 |
LogP | 3.33 |
Vapour Pressure | 0.0±2.4 mmHg at 25°C |
Index of Refraction | 1.602 |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
RIDADR | NONH for all modes of transport |
Modulation of Sleep Homeostasis by Corticotropin Releasing Hormone in REM Sleep-Deprived Rats.
Int. J. Endocrinol. 2010 , 326151, (2010) Studies have shown that sleep recovery following different protocols of forced waking varies according to the level of stress inherent to each method. Sleep deprivation activates the hypothalamic-pitu... |
|
Play fighting and corticotropin-releasing hormone in the lateral septum of golden hamsters.
Neuroscience 169 , 236-45, (2010) This study was focused on determining the possible role of corticotropin-releasing hormone (CRH) on play fighting in juvenile golden hamsters. As no specific neural sites have been proposed, we looked... |
MFCD00081543 |